Amylin analogue

Pramlintide

Prepared by the ezGLP team. Sources last checked September 5, 2026.

Also known as Pramlintide acetate

Routes represented in the knowledgebase: Subcutaneous (SubQ).

Educational overview

FDA-approved only as an adjunct to mealtime insulin; severe hypoglycemia is a boxed warning when used with insulin.

Category: Amylin analogue
Routes represented: Subcutaneous (SubQ)
Approximate library half-life: 0.8 hours; formulation-dependent and not dosing guidance
Storage context: Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.

Authoritative overview

Published literature

No validated PubMed or DOI link is currently curated for this entry.

Safety evidence

Common or reported: nausea, vomiting, reduced appetite, headache, abdominal pain, fatigue, dizziness.

Serious or important: severe hypoglycemia with insulin, hypersensitivity.

Safety evidence source

Interaction evidence

These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.

With mealtime insulin

Safety flag

Pramlintide carries a boxed warning for severe hypoglycemia when used with insulin.

Interaction evidence source

With GI-motility or nutrient-absorption medicines

Safety flag

Combined gastric-emptying or nutrient-absorption effects have not been adequately studied.

Interaction evidence source

With GLP-1, incretin, or additional amylin therapy

Safety flag

Additive gastric-emptying delay, GI intolerance, and glucose lowering are plausible; a broad clinical contraindication is not established.

Interaction evidence source

With mealtime insulin

Complementary evidenceLv3

Pramlintide is labeled as an adjunct to mealtime insulin and can reduce post-meal glucose excursions when the combination is carefully managed.

Interaction evidence sourceHuman trialHuman trial

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.